X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse IPCA Labs with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs MYLAN (US) - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 IPCA LABS   MYLAN
EQUITY SHARE DATA
    IPCA LABS
Mar-18
MYLAN
Dec-14
IPCA LABS/
MYLAN
5-Yr Chart
Click to enlarge
High Rs6954,183-   
Low Rs4002,948-   
Sales per share (Unadj.) Rs260.21,431.9-  
Earnings per share (Unadj.) Rs19.0172.5-  
Cash flow per share (Unadj.) Rs33.1277.7-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.0711.8-  
Shares outstanding (eoy) m126.20378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x2.12.5 84.5%   
Avg P/E ratio x28.920.7 139.7%  
P/CF ratio (eoy) x16.612.8 129.0%  
Price / Book Value ratio x2.65.0 51.3%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,1201,348,943 5.1%   
No. of employees `00013.325.0 53.0%   
Total wages/salary Rs m7,3590-   
Avg. sales/employee Rs Th2,477.421,671.6 11.4%   
Avg. wages/employee Rs Th555.20-   
Avg. net profit/employee Rs Th180.62,610.7 6.9%   
INCOME DATA
Net Sales Rs m32,836541,790 6.1%  
Other income Rs m418-3,158 -13.2%   
Total revenues Rs m33,254538,632 6.2%   
Gross profit Rs m4,505134,746 3.3%  
Depreciation Rs m1,77739,792 4.5%   
Interest Rs m24023,370 1.0%   
Profit before tax Rs m2,90568,426 4.2%   
Minority Interest Rs m0-281 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5112,877 17.8%   
Profit after tax Rs m2,39465,267 3.7%  
Gross profit margin %13.724.9 55.2%  
Effective tax rate %17.64.2 418.3%   
Net profit margin %7.312.0 60.5%  
BALANCE SHEET DATA
Current assets Rs m19,455476,305 4.1%   
Current liabilities Rs m10,076372,375 2.7%   
Net working cap to sales %28.619.2 148.9%  
Current ratio x1.91.3 151.0%  
Inventory Days Days9878 125.4%  
Debtors Days Days67107 62.4%  
Net fixed assets Rs m20,260125,341 16.2%   
Share capital Rs m25219,159 1.3%   
"Free" reserves Rs m26,6330-   
Net worth Rs m26,886269,323 10.0%   
Long term debt Rs m2,340402,342 0.6%   
Total assets Rs m41,1731,084,807 3.8%  
Interest coverage x13.13.9 333.4%   
Debt to equity ratio x0.11.5 5.8%  
Sales to assets ratio x0.80.5 159.7%   
Return on assets %6.48.2 78.3%  
Return on equity %8.924.2 36.7%  
Return on capital %10.813.6 79.0%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Net fx Rs m10,7590-   
CASH FLOW
From Operations Rs m3,41171,219 4.8%  
From Investments Rs m-1,354-56,165 2.4%  
From Financial Activity Rs m-1,304-18,766 6.9%  
Net Cashflow Rs m753-3,713 -20.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 70.18 Rs / USD

Compare IPCA LABS With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare IPCA LABS With: DISHMAN PHARMA  ALKEM LABORATORIES  TTK HEALTHCARE  BIOCON LTD  GLENMARK PHARMA  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views On News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 17, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS